Group One Trading
VVOS icon

Group One Trading’s Vivos Therapeutics VVOS Stock Holding History

Group One Trading’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-116
Closed -$8K – 8601
2022
Q1 		$8K Sell
116
-4
-3% -$262 ﹤0.01% 7265
2021
Q4 		$7K Buy
120
+64
+114% +$5.15K ﹤0.01% 7537
2021
Q3 		$6K Buy
+56
New +$5.89K ﹤0.01% 7699

Other funds holding VVOS

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Group One Trading's VVOS Position: Q2 2025 in Review

Group One Trading sold out of Vivos Therapeutics (VVOS) in Q2 2025, closing a stake of 228 shares — an estimated $650 sold.

Group One Trading first reported a position in VVOS in Q3 2021 and held it in 15 quarters. The position peaked at $180K in Q1 2022. 19 funds tracked by Wall St. Rank hold VVOS as of Q2 2025.

  • Group One Trading reported no remaining Vivos Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Group One Trading sold 228 Vivos Therapeutics shares in Q2 2025, an estimated $650.
  • Group One Trading first reported a position in Vivos Therapeutics in Q3 2021 and held it in 15 quarters.
  • Group One Trading's Vivos Therapeutics position peaked at $180K in Q1 2022.
  • 19 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q2 2025.

Based on Group One Trading's 13F filing for Q2 2025, filed 14 Aug 2025.